×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRKR – marker therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRKR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
06:02 am
mrkr
Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/14
08:10 am
mrkr
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
11/14
07:00 am
mrkr
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Medium
Report
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
11/5
07:30 am
mrkr
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
Low
Report
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
11/3
09:15 am
mrkr
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Low
Report
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
10/6
07:39 am
mrkr
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program [Yahoo! Finance]
Medium
Report
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program [Yahoo! Finance]
10/6
07:30 am
mrkr
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Medium
Report
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
04:21 pm
mrkr
Form 4 Marker Therapeutics, For: Nov 17 Filed by: Knobil Katharine
Medium
Report
Form 4 Marker Therapeutics, For: Nov 17 Filed by: Knobil Katharine
11/19
04:10 pm
mrkr
Form 4 Marker Therapeutics, For: Nov 17 Filed by: Eansor Norman David
Medium
Report
Form 4 Marker Therapeutics, For: Nov 17 Filed by: Eansor Norman David
11/19
04:01 pm
mrkr
Form 4 Marker Therapeutics, For: Nov 17 Filed by: ELMS STEVE
Medium
Report
Form 4 Marker Therapeutics, For: Nov 17 Filed by: ELMS STEVE
11/17
04:23 pm
mrkr
Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
Medium
Report
Form SCHEDULE 13D/A Marker Therapeutics, Filed by: New Enterprise Associates 16, L.P.
11/14
08:09 pm
mrkr
Form SCHEDULE 13G/A Marker Therapeutics, Filed by: Alyeska Investment Group, L.P.
Low
Report
Form SCHEDULE 13G/A Marker Therapeutics, Filed by: Alyeska Investment Group, L.P.
11/14
07:21 am
mrkr
Form 8-K Marker Therapeutics, For: Nov 14
Medium
Report
Form 8-K Marker Therapeutics, For: Nov 14
11/5
07:37 am
mrkr
Form 8-K Marker Therapeutics, For: Oct 31
Low
Report
Form 8-K Marker Therapeutics, For: Oct 31
11/4
05:09 pm
mrkr
Form 4 Marker Therapeutics, For: Oct 31 Filed by: Corzo Kathryn Penkus
Low
Report
Form 4 Marker Therapeutics, For: Oct 31 Filed by: Corzo Kathryn Penkus
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/29
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia
15.8%
8/15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs 15.0%
8/6 Marker Therapeutics Appoints Steve Elms to its Board of Directors 12.4%
4/10 FDA grants emergency authorization to two blood purification systems [MarketWatch] 10.9%
6/20 Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma 9.0%
5/9 Q1/2019 3/31/2019 EPS -0.120 ZacksConsensus N/A ActVsEst N/A - N/A 7.5%
3/2 Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million 6.7%
11/11 Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019 5.0%
8/8 Form 4 Marker Therapeutics, For: Aug 06 Filed by: ELMS STEVE 4.5%
8/13 TapImmune Inc. (NASDAQ: MRKR) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $16.00 price target on the stock. 4.4%
8/15 Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs 15.0%
8/6 Marker Therapeutics Appoints Steve Elms to its Board of Directors 12.4%
4/10 FDA grants emergency authorization to two blood purification systems [MarketWatch] 10.9%
6/20 Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma 9.0%
5/9 Q1/2019 3/31/2019 EPS -0.120 ZacksConsensus N/A ActVsEst N/A - N/A 7.5%
3/2 Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million 6.7%
11/11 Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019 5.0%
8/8 Form 4 Marker Therapeutics, For: Aug 06 Filed by: ELMS STEVE 4.5%
8/13 TapImmune Inc. (NASDAQ: MRKR) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $16.00 price target on the stock. 4.4%
TOP News Decliners
11/12
Form 10-Q Marker Therapeutics, For: Sep 30
-29.7%
7/19 Form 8-K Marker Therapeutics, For: Jul 19 -19.0%
3/12 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -16.8%
5/2 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. -8.2%
10/9 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth [Yahoo! Finance News] -6.5%
7/20 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR -5.8%
4/28 TapImmune Inc. (NASDAQ: MRKR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.7%
2/5 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.3%
2/11 Form 8-K Marker Therapeutics, For: Feb 11 -5.0%
4/21 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -5.0%
7/19 Form 8-K Marker Therapeutics, For: Jul 19 -19.0%
3/12 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -16.8%
5/2 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock. -8.2%
10/9 We Think Marker Therapeutics (NASDAQ:MRKR) Can Afford To Drive Business Growth [Yahoo! Finance News] -6.5%
7/20 Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR -5.8%
4/28 TapImmune Inc. (NASDAQ: MRKR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.7%
2/5 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.3%
2/11 Form 8-K Marker Therapeutics, For: Feb 11 -5.0%
4/21 TapImmune Inc. (NASDAQ: MRKR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: